Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02086786 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia
A Phase 2 study, sponsored by Rovi Pharmaceuticals Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT02086786: Completed Phase 2 study, sponsored by Rovi Pharmaceuticals Laboratories.
NCT02086786 is a Phase 2 study that has completed, run by Rovi Pharmaceuticals Laboratories. The registered enrollment target is 70 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02086786, a Phase 2 study, has completed, sponsored by Rovi Pharmaceuticals Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
To characterize the pharmacokinetics (PK) of the injectable intramuscular (IM) long-acting formulation (in situ microparticle, ISM) of risperidone over four IM injections in the gluteal and deltoid muscle at 28-day intervals and at one dose strength (75 mg) in patients with schizophrenia.
Interventions
- DRUG Risperidone ISM
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2014-03 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
What the finished NCT02086786 record still lists
NCT02086786 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 70 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 1 intervention - of which Risperidone ISM is the first listed.
NCT02086786 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02086786 about?
NCT02086786 is a clinical study titled "Pharmacokinetics and Tolerability Study of Risperidone ISM® in Schizophrenia". To characterize the pharmacokinetics (PK) of the injectable intramuscular (IM) long-acting formulation (in situ microparticle, ISM) of risperidone over four IM injections in the gluteal and deltoid muscle at 28-day intervals and at one dose strength (75 mg) in patients with schizophrenia.
What is the current status of trial NCT02086786?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2014-03. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02086786?
The interventions under investigation include: Risperidone ISM (DRUG).
Who is sponsoring clinical trial NCT02086786?
This trial is sponsored by Rovi Pharmaceuticals Laboratories, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02086786's enrollment target sits among peer trials
70 937th of 2000 higher than 1,036 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00969111 · 70 participants · NA
Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy
- NCT01712620 · 70 participants · Phase 2
Spironolactone for Pulmonary Arterial Hypertension
- NCT02143830 · 70 participants · Phase 2
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
- NCT02601339 · 70 participants
NIRS Monitoring in Premature Infants
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia